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Neonatal diabetes is defined as diabetes diagnosed within the first six months of life. It is highly genetically heterogeneous, with dominant, recessive and X-linked patterns of inheritance well described, comprising to date over 20 distinct syndromic and non-syndromic forms with a combined incidence of around 1 in 100,000 births [1]. 

During infancy and early childhood, type 1 predominates and type 2 diabetes is becoming more common.  However, monogenic causes of diabetes should also be considered in this group.  Examples of syndromic monogenic diabetes in this age range include Wolfram syndrome [2], Thiamine Responsive Megaloblastic Anaemia (TRMA) [3], and diabetes due to heterozygous mutations in the transcription factor GATA6, a cause of neonatal diabetes in association with congenital heart and other malformations [4].

Biallelic mutations in RFX6 (regulatory factor X, 6) cause neonatal diabetes mellitus in association with intestinal atresias, and hepatobiliary abnormalities.  This condition has been designated Mitchell-Riley syndrome [6].  To date there have been 8 genetically confirmed cases, comprising 7 probands and one sibling [6, 8-12]. Typically, fetal abnormality is suspected pre-natally and a diagnosis of duodenal and/or jejunal atresia confirmed shortly after birth.  Low birth weight and ongoing feeding difficulties relating to bowel surgery contribute to failure to thrive.  Cholestasis, partly secondary to total parenteral nutrition and partly due to a poorly defined primary intrahepatic cholangiopathy may result in hepatic failure.  Neonatal diabetes is diagnosed within the first few weeks of life. Prognosis is poor, with death occurring within the first six months in 5 of the cases described to date.  







Clinical reports and results

Case 1 (Figure 1, I5), current age 9 years, is a female born at 32 weeks’ gestation, birth weight 1.65 kg (42nd centile), with duodenal atresia, jejunal web and Meckel’s diverticulum. She underwent operative intervention for these malformations before being discharged from hospital at 3 months of age.  During an admission at the age of two years, hyperglycemia (10.6 mmol/l) had been noted.  However, no further investigation or treatment was put in place at that time. She presented at the age of 3 years with diabetic ketoacidosis. Physical examination revealed no abnormalites other than those associated with diabetic ketoacidosis. Her body weight was 18.5 kg (10th-25th centile). Height was 118 cm (25th – 50th centile). Investigations showed blood glucose 33.0 mmol/l; insulin <2 µIU/ml, C-peptide 0.023 ng/ml, blood pH: 7.40; urine ketone: +++, HbA1c 8.96%, anti GAD, IAA, ICA negative. She was prescribed a dose of 0.35 U/kg/day of long-acting insulin with occasional bolus insulin.  
 
Otherwise, her past medical history was notable for multiple hospital admissions due to gastrointestinal bleeding.  At the age of 5 years, she underwent a small intestinal resection, histological examination of which revealed the presence of patches of gastric heterotopia within the small bowel.  Her gastro-intestinal bleeding subsequently resolved.

Additional investigation revealed absent gall bladder with otherwise normal biliary tract.  Liver function tests have always been within normal limits.
   
She has a healthy 16 year-old sister. A brother died of prematurity and meconium aspiration at one week of age.  An identical twin was diagnosed with duodenal atresia and underwent corrective surgery at two days of age. She died of complications of prematurity and surgery at the age of one month.  

Case 2 (Figure 1, I12), her double first cousin, current age 9 years, is a male infant born at 34 weeks gestation, birth weight 1.70 kg (7th centile), with duodenal atresia and mid-gut malrotation.  He was diagnosed with diabetes having presented with hyperglycaemia (16.0 mmol/l) at the age of 6 years.  He had no prior symptoms suggestive of diabetes and hyperglycemia had been identified at home by his mother.  He did have a history of asymptomatic fasting hyperglycemia (7.2 mmol/l) determined one year previously in another hospital; no treatment was initiated at that time. 

Physical examination was unremarkable. His body weight was 17.5 kg (10th centile). Height was 113 cm (25th centile). Investigations at this time showed: blood glucose 16.0 mmol/l; insulin: <2 µIU/ml; C-peptide 0.39 ng/ml, blood: pH: 7.41; urine ketones: negative; HbA1C: 7.96 %.  Anti-GAD, IAA, ICA antibodies negative.  He was followed-up with intensive insulin regimen and requires low dose of insulin.  

His past history is notable for chronic iron deficiency anemia.  Despite extensive investigation at two different hospitals, it has not been possible to identify a cause for this.  No structural abnormality of the hepato-biliary tract has been identified, and his liver function tests have always been within normal limits.

He has healthy sisters, current ages 20 and 11 years. Another sister died of cerebral palsy at the age of 17 years. A brother died of complications of prematurity at one week of age. His mother was diagnosed with diabetes 4 years previously. 

There was no history of parental consanguinity.  However, the mothers of the two cases are sisters and the fathers are brothers, making the affected individuals double first cousins.

Genetic testing showed that both children are compound heterozygotes for the RFX6 nonsense mutations c.2176C>T (p.Arg726X) and c.2596C>T (p.Arg866X) in exons 17 and 18 respectively (Figure 2).  The fathers were heterozygous for p.Arg726X and the mothers heterozygous for p.Arg866X.   Further testing demonstrated that the mutations had been inherited from both maternal grandmothers.  

Other family members had been diagnosed with diabetes in adulthood, as shown in the pedigree and in Table 2.  The mother of case 2, both maternal grandmothers and the surviving (maternal) grandfather (Figure 1, II6, III2, III4 and III3, respectively) developed adult-onset diabetes.  Age of diagnosis for these four individuals is provided in Figure 1.   All four are non-obese (BMI data not available) and treated with an oral hypoglycaemic agent.  C-peptide and HbA1c levels were assayed in all four heterozygote parents and in both heterozygote grandmothers, and, for comparison, in one further non-diabetic heterozygote and a further eight non-diabetic family members without a mutation (See Figure 1).  For heterozygotes in the family, there was no significant difference in C-peptide levels between those who had and had not developed diabetes.  There was also no difference in HBA1c between the non-diabetic heterozygotes and those who are negative for the relevant familial mutation.  Taking these data together, there is no support for the idea that being heterozygous for either RFX6 mutation is a risk factor for abnormal HbA1c or C-peptide levels, or diabetes.










We report double first cousins in whom the identification of biallelic RFX6 mutations has confirmed a diagnosis of Mitchell-Riley syndrome.  These new cases are the first with Mitchell-Riley syndrome in whom the diagnosis of diabetes was not made in the neonatal period, all other cases to date having been diagnosed within the first two weeks of life.  The diagnosis of diabetes in these cousins at the ages of 3 and 6 years is therefore significantly different from the previously expected phenotype.  In both of the cousins, a period of asymptomatic hyperglycemia of at least one year preceded a formal diagnosis of diabetes.

The results of mutation analysis of the eight molecularly confirmed probands suggest a possible genotype/phenotype correlation.  Of the nine mutations identified in these eight cases (one a compound heterozygote, the remaining seven homozygous),  six affect splicing and/or the reading frame in exons 2-8; the remaining three are mis-sense mutations clustering within or close to the DNA-binding domain (Figure 2).  The cases in the present report are compound heterozygotes for premature truncating mutations in exons 17 and 18 of the 19 exon RFX6 gene.  The exon 18 mutation, c.2596C>T (R866X) is predicted to escape nonsense-mediated decay because it lies within 50 nucleotides of the last exon-exon boundary of the gene.  A partially truncated version of the wild type protein, which comprises 928 amino acids, is therefore predicted to be produced, possibly with some function given the full preservation of the DNA binding domain.  The second mutation, c.2176C>T (R726X), is predicted to be subject to nonsense-mediated decay.  

There are reports in the literature of distinct phenotypes associated with mutated transcripts depending upon the presence or absence nonsense-mediated decay.  3’ mutations in SOX10 result in a severe neurocristopathy designated PCWH [13].  More 5’ mutations result in the more restricted phenotype of Waardenburg-Shah syndrome.  Transcripts with 3’ mutations escape nonsense-mediated decay and in this instance the phenotype is postulated to be more severe than that due to more 5’ mutations because failure of the NMD pathway results in production of a protein with a dominant negative effect.   A distinct clinical phenotype is also postulated in instances of 3’ mutations in the FBN1 gene, with the same proposed mechanism of escape from NMD [14].  

In the present case of biallelic mutations in RFX6, the transcript with the 3’-most RFX6 mutation (c.2596C>T) is predicted to escape NMD, a possibility which could be tested by analyzing levels of wild type and mutated transcripts in a suitable experimental assay.  It is possible that escape from NMD could lead to some retention of function of the RFX6 protein generated from that allele, with a resulting milder phenotype with respect to age of onset of diabetes and other clinical features.  Such experimental work is however beyond the scope of the present manuscript, given that a cell line from the patient, or an alternative source of RNA from a tissue in which RFX6 is expressed, was not available. The identification of further cases with mutations in this region of the gene may lend further support to this hypothesis.  

The data presented support the idea that biallelic mutations in RFX6 should be considered in any infant presenting with duodenal or jejunal atresia with or without intestinal malrotation, especially in the context of possible autosomal recessive inheritance.  A genetic diagnosis confers not only the advantage of establishing a molecular genetic diagnosis, but also alerts the clinician to the future possibilities of onset of diabetes during infancy or childhood, as well as possible hepatobiliary complications.













Cases of Mitchell-Riley syndrome were identified from Pubmed (http://www.ncbi.nlm.nih.gov/pubmed). Those cases in whom confirmatory biallelic mutations in RFX6 had been identified were included in our review.
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a)	RFX6 gene structure.  Exons are shown in blue with exon numbers underneath.  Mutations are shown preceded by a number in brackets which denotes the case in Table 1 to which it refers.
b)	RFX6 protein schematic.  The DNA-binding domain is shown as a blue box.  Amino acid numbering is shown, together with amino acid changes due to mis-sense or nonsense mutations. The number in parenthesis preceding each amino acid change denotes the case in Table 1 to which it refers.  The mutations in the patients who are the subjects of the present report are the only ones so far reported in any of exons 9-19, all others occurring in exons 1-8, or the intervening introns.








